학술논문
310 Efficacy and safety of abrocitinib in biologic-exposed versus biologic-naïve patients with moderate-to-severe atopic dermatitis
Document Type
Abstract
Author
Source
In Journal of Investigative Dermatology August 2022 142(8) Supplement:S53-S53
Subject
Language
ISSN
0022-202X